Sanjay Gandhi to Huntington Disease
This is a "connection" page, showing publications Sanjay Gandhi has written about Huntington Disease.
Connection Strength
0.641
-
McGarry A, Auinger P, Kieburtz K, Geva M, Mehra M, Abler V, Grachev ID, Gordon MF, Savola JM, Gandhi S, Papapetropoulos S, Hayden M. Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease. J Huntingtons Dis. 2020; 9(2):173-184.
Score: 0.178
-
Thorley EM, Iyer RG, Wicks P, Curran C, Gandhi SK, Abler V, Anderson KE, Carlozzi NE. Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. Patient. 2018 10; 11(5):547-559.
Score: 0.163
-
Sung VW, Iyer RG, Gandhi SK, Shah-Manek B, DiBonaventura M, Abler V, Claassen DO. Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States. Curr Med Res Opin. 2018 04; 34(4):643-648.
Score: 0.156
-
McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease. J Huntingtons Dis. 2017; 6(3):189-199.
Score: 0.144